PRESS RELEASE IDF Cogress 2015

PRESS RELEASE

South-South cooperation to improve diabetes care

China, Zimbabwe and Ecuador will have an exclusive opportunity to replicate and adapt a successful diabetic foot care project originally developed in Alexandria, Egypt. This pioneering partner approach to diabetes care is a first of its kind South-South cooperation for the International Diabetes Federation (IDF). A South-South cooperation promotes the sharing of best practices in research and prevention between low and middle income countries.

With the support of the IDF BRIDGES programme, three diabetes centres in the selected countries, will benefit from the partnership:

-Qingdao Endocrine and Diabetes Hospital, Qingdao (China)

-Zimbabwe Diabetes Association, Harare (Zimbabwe)

-Ambulatory healthcare center “CAA Cotocollao”, Quito (Ecuador)

Prior to the start of the intervention, local teams in these centres will be trained during workshops organized by Professor Samir Khalil, principal investigator of the original project in Egypt and IDF. These four day workshops will strengthen the intervention and ensure the success of its implementation.

“We are building bridges between scientists and diabetes communities worldwide through a unique South-South cooperation” said Sir Michael Hirst, President of IDF. “With over 80% of the people living with diabetes in low and middle income countries, the transfer of knowledge and expertise between these regions is key to tackle the diabetes epidemic and reduce complications”.

“After successful results in Egypt, we are excited to share our foot care project with the rest of the world” stated Professor Khalil. “In less than two years in Egypt, we managed to educate more than 2,700 professionals nationwide. Almost all universities now have a module on diabetes foot care included in their graduate and post graduate curriculum”.

For more information contact:

Ronan L’Heveder, ronan.lheveder@idf.org

About the International Diabetes Federation (IDF)

The International Diabetes Federation (IDF) is an umbrella organization of over 230 national diabetes associations in 170 countries and territories. It represents the interests of the growing number of people with diabetes and those at risk. The Federation has been leading the global diabetes community since 1950. www.idf.org

About IDF’s BRIDGES programme

BRIDGES is a programme of the International Diabetes Federation supported by an educational grant from Lilly Diabetes. BRIDGES is dedicated to translational research and is supporting 41 projects in 38 countries in primary and secondary prevention of diabetes. More information is available on www.idf.org/bridges

 

IDF 2015 Press Releases

Press Release

For Non-US and Non-UK Media

For distribution: 10:00 a.m. CEST, 15 June 2014

[Embargo: 10:00 a.m. Pacific Time, 14 June 2014]

Poster Number: 62-LB

Type 2 Diabetes: Physicians worldwide agree early conversations are crucial in the management of condition

·         First insights from IntroDia™, the largest multinational survey of its kind, are presented at the American Diabetes Association’s (ADA) 74th  Scientific Sessions®

·         Physicians believe early conversations with people diagnosed with Type 2 Diabetes are crucial, but many report a variety of challenges at the point of diagnosis

·         IntroDia™ is currently ongoing and has been developed by Boehringer Ingelheim and Lilly, in partnership with the International Diabetes Federation (IDF)

Ingelheim, Germany and Indianapolis, US, 15 June 2014 – The first insights from IntroDia™ presented at the American Diabetes Association’s (ADA) 74th Scientific Sessions®, showed that over three quarters (76-100 percent across 26 countries) of 6,753 physicians surveyed agree that conversations at diagnosis impact the way people with Type 2 Diabetes (T2D) accept their condition and their treatment adherence.1 Despite the importance of these conversations, the preliminary data also indicated many physicians

report a variety of challenges during the diagnosis conversations.1

According to data presented, the challenges most commonly reported by physicians during diagnosis conversations are that patients do not keep up with the required changes, returning back to old habits, in addition to physicians not having enough time to carry out these important conversations with patients.1

Most physicians (92 percent) surveyed also indicated they would like tools to help people with T2D sustain behavioural change.

Ms. Anne Belton, Vice President of the International Diabetes Federation, and member of the IntroDia™ Advisory Board commented: “These preliminary results from the IntroDia™ survey build on previous studies, which demonstrated that early conversations have an impact in the management of diabetes and can impact patient outcomes. We look forward to the full results, which will provide a deeper understanding of the challenges and barriers for both physicians and people with Type 2 Diabetes.  We hope to then provide support to physicians to help them improve those conversations which we believe will result in better outcomes for people with Type 2 Diabetes.”

The IntroDia™ survey is ongoing, and the next set of results will include insights from people with T2D. The IntroDia™ survey will include insights from 6,753 physicians and approximately 10,000 people with

T2D, and is investigating early T2D conversations. The survey results will be used to develop tools to

provide additional support for physicians and people with T2D during their early conversations.

About IntroDia™

IntroDia™, developed by Boehringer Ingelheim GmbH (BI) and Eli Lilly and Company in partnership with the International Diabetes Federation (IDF), is the largest multinational survey of its kind to date which aims to investigate early conversations between physicians and people living with T2D, and how these conversations may correlate with the individuals’ wellbeing and self-care.

The IntroDia™ survey is part of the BI and Lilly Diabetes alliance’s commitment to providing continuous support to physicians and people with T2D, and is concentrated on the needs and realities of primary care. It utilises a combination of both validated tools and new research approaches to investigate the early conversations in T2D. The full insights from the survey will focus on what physicians and patients take away from these conversations and how this is associated with patient wellbeing and other self- reported patient outcomes. These insights will then be used to develop tools to provide additional support for physicians and people with T2D for their early conversations.

Also involved in the IntroDia™ survey is an international advisory board of professional experts, including: Ms. Anne Belton, Canada; Dr. Steven Edelman, USA; Dr. William Polonsky, USA; Dr. Matthew S Capehorn, UK and Ms. Susan Down, UK.

For more details, please visit www.introdia.com

Boehringer Ingelheim and Eli Lilly and Company

In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance in diabetes that centers on compounds representing several of the largest diabetes treatment classes. The alliance leverages the strengths of two of the world’s leading pharmaceutical companies. By joining forces, the companies demonstrate commitment in the care of patients with diabetes and stand together to focus on patient needs. Find out more about the alliance at www.boehringer-ingelheim.com or www.lilly.com .

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 142 affiliates and a total of more than 47,400 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Taking social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2013, Boehringer Ingelheim achieved net sales of about €14.1 billion. R&D expenditure corresponds to 19.5% of its net sales.

For more information please visit http://www.boehringer-ingelheim.com

About Lilly Diabetes

Lilly has been a global leader in diabetes care since 1923, when we introduced the world’s first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research and collaboration, a broad and growing product portfolio and a continued determination to provide real solutions—from medicines to support programs and more—we strive to make life better for all those affected by diabetes around the world. For more information, visit www.lillydiabetes.com.